Youssef Rddad

Seattle

Staff Writer at Oncology News Central

Journalist, composer, @theadvocatebr, @arkansasonline and @AP alumn.

Featured in: Favicon

theadvocate.com Favicon

foxnews.com Favicon

washingtonpost.com Favicon

latimes.com Favicon

sfgate.com Favicon

usnews.com Favicon

yahoo.com (+1) Favicon

apnews.com + 111 more

Articles

First Studies Reported Ahead of 2025 ASCO Annual Meeting

2 weeks ago | oncologynewscentral.com | Youssef Rddad

Advances in treating certain lung and breast cancers, an artificial intelligence tool that helps identify HER2 status, and the potential for GLP-1 agonists to lower cancer risks were among the studies highlighted at the first news conference ahead of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This year’s conference runs from May 30 to June 3 in Chicago and will feature more than 6,000 abstracts, including practice-changing data across multiple diseases.
Emerging Data Challenge Current Breast Cancer Treatment Algorithms

2 weeks ago | oncologynewscentral.com | Youssef Rddad

Emerging data suggest that liquid biopsy and circulating tumor DNA (ctDNA) monitoring could soon reshape treatment paradigms for clinicians managing hormone receptor–positive, ESR1-mutated breast cancer. Although traditional approaches rely on clinical signs of progression, new studies indicate that early detection of ESR1 mutations may allow for proactive therapeutic shifts before disease progression.
Trispecifics and Bispecific Combos Poised to Transform Myeloma Care?

2 weeks ago | oncologynewscentral.com | Youssef Rddad

Recent research in multiple myeloma, along with data set to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting,may soon transform clinical practice in multiple myeloma, experts say. The most closely watched developments include studies examining bispecific antibody combinations, new CAR-T therapy targets, and early data on trispecific antibodies.
Without Key Data, Expanded Treatment Options Complicate Gastric Cancer Care

2 weeks ago | oncologynewscentral.com | Youssef Rddad

For clinicians treating patients with HER2-negative gastric and gastroesophageal junction (GEJ) cancers, immune checkpoint inhibitors and claudin 18.2–targeted therapies have expanded biomarker-driven options. However, when both treatments are viable choices, decision-making can be challenging.
FDA Approves Retifanlimab (Zynyz) for Advanced Anal Cancer

3 weeks ago | oncologynewscentral.com | Youssef Rddad

On May 15, the U.S. Food and Drug Administration (FDA) approved frontline retifanlimab-dlwr (Zynyz) plus platinum-based chemotherapy for adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The agency also approved retifanlimab as monotherapy for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
FDA Approves First Oral Drug for Pheochromocytoma or Paraganglioma

3 weeks ago | oncologynewscentral.com | Youssef Rddad

On May 14, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg) for adults and children age 12 years and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma (PPGL). The approval of belzutifan, an HIF-2α inhibitor, marks the first oral treatment to be approved by the FDA for PPGL. The agency based its decision on results from the open-label, phase 2 LITESPARK-015 clinical trial.
FDA Approves Telisotuzumab Vedotin (Emrelis) for Advanced NSCLC

3 weeks ago | oncologynewscentral.com | Youssef Rddad

On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for adults with previously treated, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.The antibody-drug conjugate is the first treatment approved for this patient population with NSCLC, according to a news release from the manufacturer, AbbVie.
FDA Approves First-Ever Drug Combination for Low-Grade Serous Ovarian Cancer

4 weeks ago | oncologynewscentral.com | Youssef Rddad

The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received previous systemic therapy. This marks the first-ever FDA approval for this disease, according to a statement from the manufacturer, Verastem Oncology. The FDA based its decision on results from the open-label, multicenter, single-group, phase 2 RAMP 201 clinical trial.
FDA Must Explain “Confounding” Bladder Cancer Drug Rejection, Company Says

1 month ago | oncologynewscentral.com | Youssef Rddad

A California-based drugmaker says that the U.S. Food and Drug Administration (FDA) refused to accept its application for its bladder cancer drug despite what the company described as unanimous guidance and encouragement from agency leaders to file months earlier.
Treatment Device Posts “Highest Complete Response Rate Reported to Date” in Bladder Cancer Trial

1 month ago | oncologynewscentral.com | Youssef Rddad

Patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (NMIBC) demonstrated durable responses after treatment with a novel, intravesical drug delivery system. The results were based on findings from the ongoing phase 2b SunRISe-1 trial, which were presented at the 2025 American Urological Association Annual Meeting in Las Vegas and published in The Journal of Urology.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 1K
Tweets: 4K
DMs Open: Yes

No Tweets found.